A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer

The mortality rate in patients suffering from non-small cell lung cancer (NSCLC) is quite high. This type of cancer mainly occurs due to rearrangements in the anaplastic lymphoma kinase (ALK) gene which leads to form an oncogene of fused gene NPM-ALK. Brigatinib is recently approved by FDA in April...

書誌詳細
出版年:	Saudi Pharmaceutical Journal
主要な著者:	Silky Bedi, Shah A. Khan, Majed M. AbuKhader, Perwez Alam, Nasir A. Siddiqui, Asif Husain
フォーマット:	論文
言語:	英語
出版事項:	Springer 2018-09-01
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S1319016418300902

類似資料

Recent Advances in the Treatment of Non-small Cell Lung Cancer with Brigatinib
著者:: Jia YU, 等
出版事項: (2025-06-01)

Pleuritis Induced by Brigatinib During the Treatment of Non‐Small Cell Lung Cancer
著者:: Shohei Yano, 等
出版事項: (2026-05-01)

Development of a stress induced validated UPLC-PDA method for the analysis of Eslicarbazepine acetate
著者:: Farah Iram, 等
出版事項: (2018-02-01)

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK‐positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib
著者:: Yuki Sato, 等
出版事項: (2024-08-01)

A Case of Adjuvant Brigatinib in a Patient with ALK-rearranged R0 Resected Oligometastatic Lung Cancer
著者:: Oktay Ünsal, 等
出版事項: (2025-10-01)

Brigatinib-repurposed chemo-photodynamic therapy nanoplatform via effective apoptosis against colorectal cancer
著者:: Miao Su, 等
出版事項: (2023-02-01)

Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies
著者:: Bo Li, 等
出版事項: (2019-01-01)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
著者:: Ken Uchibori, 等
出版事項: (2017-03-01)

Safety of brigatinib following alectinib-induced-pneumonitis: Case report
著者:: Blerina Resuli, 等
出版事項: (2025-01-01)

Case report: Pathological complete response to neoadjuvant brigatinib in stage III non-small cell lung cancer with ALK rearrangement
著者:: Hayoung Seong, 等
出版事項: (2024-07-01)

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis
著者:: Puyuan Xing, 等
出版事項: (2022-11-01)

High efficacy of brigatinib for brain metastases in ALK fusion gene‐positive non‐small cell lung cancer: A case series
著者:: Kei Morikawa, 等
出版事項: (2024-02-01)

Successful Treatment of Osimertinib Resistance in an EGFR‐Mutant Lung Cancer Patient With a Rare STRN3‐ALK Fusion Using Brigatinib and Osimertinib
著者:: Chia‐Yu Kuo, 等
出版事項: (2025-07-01)

Unilateral cystic and bullous lung changes in a patient treated with brigatinib: a case report
著者:: Anuradha Nalika Godallage, 等
出版事項: (2025-08-01)

Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report
著者:: Daphnée Demers, 等
出版事項: (2025-05-01)

The 8th Wonder of the Cancer World: Esophageal Cancer and Inflammation
著者:: Harleen Kaur Chela, 等
出版事項: (2022-07-01)

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)
著者:: Kazushige Wakuda, 等
出版事項: (2023-09-01)

Brigatinib can inhibit proliferation and induce apoptosis of human immortalized keratinocyte cells
著者:: Qi Yang, 等
出版事項: (2025-02-01)

Jordanian Arabic Version of the Dizziness Handicap Inventory
著者:: Al Masri M, 等
出版事項: (2024-07-01)

Pharmacoeconomic Analysis of Brigatinib versus Alectinib in First‑Line Treatment of Anaplastic Lymphoma Kinase‑Positive Advanced Non‑Small‑Cell Lung Cancer in China
著者:: Qingqing Chai, 等
出版事項: (2025-07-01)

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
著者:: Wenjie Liu, 等
出版事項: (2024-02-01)

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
著者:: Xia Luo, 等
出版事項: (2022-09-01)

The wonders of X-PDT: an advance route to cancer theranostics
著者:: Asim Mushtaq, 等
出版事項: (2024-10-01)

Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements
著者:: Kyuhwan Kim, 等
出版事項: (2025-02-01)

Soluplus–TPGS Mixed Micelles as a Delivery System for Brigatinib: Characterization and In Vitro Evaluation
著者:: Raisuddin Ali, 等
出版事項: (2024-09-01)

CDC WONDER
著者:: Saad Ahmed Waqas, MBBS, 等
出版事項: (2025-08-01)

Wonder
著者:: Monika Sharma
出版事項: (2021-01-01)

Safety and Effectiveness of Brigatinib in Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Post-Marketing Surveillance Study
著者:: Claudio Martin, 等
出版事項: (2025-02-01)

Wondering about Change
著者:: Said A. M. Khamis
出版事項: (2002-06-01)

Successful Treatment with Brigatinib after Alectinib-Induced Hemolytic Anemia in Patients with Metastatic Lung Adenocarcinoma—A Case Series
著者:: Rola El Sayed, 等
出版事項: (2022-12-01)

Time of Wonder
著者:: Cynthia Marlene Morawski, 等
出版事項: (2024-08-01)

The wonders of anticoagulation
著者:: Hugo ten Cate, 等
出版事項: (2025-01-01)

Transformative Wonder
著者:: Marcianna Nosek, 等
出版事項: (2014-12-01)

Wonders of discovery
著者:: S G Damle
出版事項: (2011-01-01)

The Wonder of Delays
著者:: Alexandra T. Vazquez
出版事項: (2018-04-01)

Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK+ non‐small cell lung cancer using South Korean claims data (K‐AREAL)
著者:: Jeong Eun Lee, 等
出版事項: (2024-07-01)

Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report
著者:: Yang Zhang, 等
出版事項: (2025-01-01)

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach
著者:: Michael J. Hanley, 等
出版事項: (2024-04-01)

Early Onset Pulmonary Events and Management Strategies during the Treatment of  ALK Positive NSCLC Patients with Brigatinib
著者:: Mingyi YANG, 等
出版事項: (2023-04-01)

A Natural Wonder Drug Helps to Prevent Cancer: Garlic Oil
著者:: Sankaran MIRUNALINI, 等
出版事項: (2010-03-01)